The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
The final text of the Trans Pacific Partnership Agreement (TPP), agreed between the 12 negotiating countries in 2016, included a suite of intellectual property provisions intended to expand and extend pharmaceutical company exclusivities on medicines. It drew wide criticism for including such provisions in an agreement that involved developing countries (Vietnam, Peru, Malaysia, Mexico, Chile and Brunei Darussalam) because of the effect on delaying the introduction of low-cost generics. While developing nations negotiated transition periods for implementing some obligations, all parties would have eventually been expected to meet the same standards had the TPP come into force. While the TPP has stalled following US withdrawal, there are moves by some of the remaining countries to reinvigorate the agreement without the United States. The proponents may seek to retain as much as possible of the original text in the hope that the United States will re-join the accord in future. This article presents a comparative analysis of the impact the final 2016 TPP intellectual property chapter could be expected to have (if implemented in its current form) on the intellectual property laws and regulatory regimes for medicines in the TPP countries. Drawing on the published literature, it traces the likely impact on access to medicines. It focuses particularly on the differential impact on regulatory frameworks for developed and developing nations (in terms of whether or not legislative action would have been required to implement the agreement). The article also explores the political and economic dynamics that contributed to these differential outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, trade agreements and policies directly influence social determinants of health, affecting access to essential medicines, availability of nutritious foods, and safety of environments through economic development and regulatory frameworks (2–6).”
From Global Health Trade Summit: an AI-enhanced simulation of international trade and global health for undergraduate public health education (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLOBAL ECONOMIC PROSPECTS: THE RECESSION MAY BE OVER BUT WHERE NEXT?
(2013) · The Financial Crisis and the Global South · doi:10.2307/j.ctt183pb3w.5 · Cited by 908
Gruber, H. (2001) · Information Economics and Policy · doi:10.1016/s0167-6245(00)00028-7 · Cited by 411
Office of the United States Trade Representative
(2013) · Choice Reviews Online · doi:10.5860/choice.51-0991 · Cited by 346
Behind the scenes at the WTO: the real world of international trade negotiations
(2004) · Choice Reviews Online · doi:10.5860/choice.41-4154 · Cited by 255 · cited 2×
“The ultimate acquiescence of the developing countries to the pharmaceutical industry agenda in the TPP can be seen as the continuation of a historical trajectory that began well before TRIPS and has continued since (Jawara and Kwa, 2004).”
BackgroundThe Economic Effects of the Trans-Pacific Partnership: New EstimatesPreprint
Petri, P. A., & Plummer, M. G. (2016) · SSRN Electronic Journal · doi:10.2139/ssrn.2723413 · Cited by 202
Developing Countries and International Intellectual Property Standard‐Setting
Drahos, P. (2002) · The Journal of World Intellectual Property · doi:10.1111/j.1747-1796.2002.tb00181.x · Cited by 188 · cited 2×
“The conditions for democratic bargaining as described by Drahos (2002) (all relevant interests are represented, all parties have full information about the consequences of decisions and no one party is dominant) were eroded in the context of aggressive negotiating strategies.”
BackgroundMethodInvestments in Pharmaceuticals Before and After TRIPS
Kyle, M. K., & McGahan, A. M. (2012) · Review of Economics and Statistics · doi:10.1162/rest_a_00214 · Cited by 178 · cited 1×
“…pharmaceutical companies to invest in developing treatments for diseases that are endemic in these countries: ‘(T)he introduction of patents in developing countries has not been followed by greater R&D investment in the diseases that are most prevalent there’ (Kyle and McGahan, 2012: 1157).”
BackgroundTrade, TRIPS, and pharmaceuticals
Smith, R. D., Correa, C., & Oh, C. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61779-1 · Cited by 173 · cited 1×
“TRIPS set a new global benchmark for intellectual property (IP) rights, with the introduction of 20-year patent terms for all fields of technology, including pharmaceuticals (Smith et al., 2009).”
BackgroundGlobal value chains and development
Ravenhill, J. (2014) · Review of International Political Economy · doi:10.1080/09692290.2013.858366 · Cited by 152
Waning, B. (2009) · Bulletin of the World Health Organization · doi:10.2471/blt.08.058925 · Cited by 122 · cited 1×
“Generic competition is generally the best way of delivering medicines at an affordable cost in developing countries (Waning et al., 2009).”
BackgroundAmin, T., & Kesselheim, A. S. (2012) · Health Affairs · doi:10.1377/hlthaff.2012.0107 · Cited by 105 · cited 1×
“For example, in the United States, researchers found a total of 108 patents (granted or applied for) associated with two key HIV drugs (ritonavir and lopinavir/ritonavir), many of which were of minimal inventiveness (Amin and Kesselheim, 2012).”
BackgroundAgreement on trade-related aspects of intellectual property rights (TRIPS)
Khaw, L. T. (1994) · Cited by 102
The Trans-Pacific Partnership: Is It Everything We Feared for Health?
Labonté, R., Schram, A., & Rückert, A. (2016) · International Journal of Health Policy and Management · doi:10.15171/ijhpm.2016.41 · Cited by 80
The High Price of “Free” Trade: U.S. Trade Agreements and Access to Medicines
Lopert, R., & Gleeson, D. (2013) · The Journal of Law Medicine & Ethics · doi:10.1111/jlme.12014 · Cited by 79 · cited 4×
“Yet the two decades since TRIPS came into force have seen an expansion of ‘TRIPS-Plus’ IP rights via a plethora of subsequent bilateral and regional trade agreements, particularly those negotiated by the United States and European Union, where the majority of the world’s largest originator pharmaceutical companies are…”
BackgroundInfluentialSelf-citationRückert, A., Schram, A., Labonté, R., Friel, S., Gleeson, D., & Thow, A. M. (2016) · Critical Public Health · doi:10.1080/09581596.2016.1178379 · Cited by 79 · cited 1×
“Nonetheless, following the conclusion of the negotiations, various analyses of the TPP’s IP chapter confirmed that the final provisions could be expected to have a significant harmful effect on access to medicines (Baker, 2016; Labonte et al., 2016; Ruckert et al., 2017).”
BackgroundInfluentialSelf-citationFour Lessons for Developing Countries from the Trade Negotiations Over Access to Medicines
Drahos, P. (2007) · Liverpool Law Review · doi:10.1007/s10991-007-9014-5 · Cited by 63 · cited 1×
“This is part of a pattern of forum shifting that has continued since the TRIPS Agreement was concluded in 1994 (Drahos, 2007).”
Intellectual Property Rights and International Innovation
Park, W. G. (2007) · Cited by 55
Global Economic Prospects, January 2016
World Bank Group (2015) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0675-9 · Cited by 53
Improving regulatory capacity to manage risks associated with trade agreements
Walls, H., Smith, R., & Drahos, P. (2015) · Globalization and Health · doi:10.1186/s12992-015-0099-7 · Cited by 43 · cited 1×
“As (Walls et al., 2015) argue, the implementation of trade agreements ‘is expensive, skillintensive and requires considerable infrastructure, which smaller and poorer states especially struggle to find’.”
BackgroundThe political economy of the Trans-Pacific Partnership: a ‘21st Century’ trade agreement?
Ravenhill, J. (2016) · New Political Economy · doi:10.1080/13563467.2017.1270925 · Cited by 40 · cited 1×
“Ravenhill (2017) points out that the models for these studies do not account for the costs associated with IP protection, which could well outweigh the estimated economic benefits, at least for some countries.”
BackgroundMultilateralising Regionalism: Ideas for a WTO Action Plan on Regionalism
Baldwin, R., & Thornton, P. (2008) · Graduate Institute Geneva Institutional Repository (Graduate Institute of International and Development Studies) · Cited by 39
Trading Down: Unemployment, Inequality and Other Risks of the Trans-Pacific Partnership AgreementPreprint
Capaldo, J., Izurieta, A., & Sundaram, J. K. (2016) · RePEc: Research Papers in Economics · Cited by 39
The price of medicines in Jordan: the cost of trade-based intellectual property
Abbott, R. B., Bader, R., Bajjali, L., ElSamen, T. A., Obeidat, T., Sboul, H., Shwayat, M., & Alabbadi, I. (2012) · Journal of Generic Medicines The Business Journal for the Generic Medicines Sector · doi:10.1177/1741134312447499 · Cited by 38 · cited 1×
“A later study by Abbott et al. (2012) found a 17% increase in medicine expenditure in Jordan between 1999 and 2004, which was largely attributable to the adoption of data exclusivity.”
BackgroundBaker, B. K. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1001970 · Cited by 37 · cited 6×
“against the Canadian Government under the North American Free Trade Agreement (Baker, 2016).”
BackgroundInfluentialLexchin, J., & Gagnon, M. (2014) · Globalization and Health · doi:10.1186/1744-8603-10-30 · Cited by 36
Self-citationEmpirical Analysis of Drug Approval-Drug Patenting Linkage for High Value Pharmaceuticals
Bouchard, R. A., Hawkins, R., Clark, R. S., Hagtvedt, R., & Sawani, J. (2010) · bepress Legal Repository · Cited by 26
Townsend, B., Gleeson, D., & Lopert, R. (2016) · Asia Pacific Journal of Public Health · doi:10.1177/1010539516676338 · Cited by 24 · cited 2×
“…in the TPP and is promoting TRIPS-Plus provisions for another regional trade agreement – the Regional Comprehensive Economic Partnership, involving the 10 members of the Association of Southeast Asian Nations and the six countries with which it has free trade agreements (Townsend et al., 2016).”
BackgroundSelf-citationGleeson, D., Moir, H. V. J., & Lopert, R. (2015) · The Medical Journal of Australia · doi:10.5694/mja14.01682 · Cited by 23 · cited 4×
“(TPP Chapter 18, Footnote 30) Secondary patenting is widely acknowledged to have a significant effect on the length of pharmaceutical monopolies and on the entry of generic medicines to the market (Gleeson et al., 2015).”
BackgroundInfluentialSelf-citationPatents Associated with High-Cost Drugs in Australia
Christie, A. F., Dent, C., McIntyre, P., Wilson, L. R., & Studdert, D. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060812 · Cited by 21 · cited 1×
“An Australian study of patents on 15 high-cost drugs found an average of 49 secondary patents for each of them (Christie et al., 2013).”
BackgroundThe Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia
Lexchin, J., & Gleeson, D. (2016) · International Journal of Health Services · doi:10.1177/0020731416662612 · Cited by 20 · cited 4×
“, 2016) or analysed the impact on specific countries (Lexchin and Gleeson, 2016; Moir et al., 2016).”
BackgroundInfluentialSelf-citationDo Pharmaceutical Firms Invest More Heavily in Countries with Data ExclusivityPreprint
Palmedo, M. (2013) · SSRN Electronic Journal · Cited by 10
The Trans-Pacific Partnership Agreement and Implications for Access to Essential Medicines
Luo, J., & Kesselheim, A. S. (2015) · JAMA · doi:10.1001/jama.2015.10872 · Cited by 9 · cited 1×
“Successive leaks of the draft IP chapter in 2013 and 2014 showed some mitigation of the initial US proposals, but many of the problematic provisions remained in the text (Gleeson et al., 2015; Luo and Kesselheim, 2015).”
BackgroundThe Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam
Moir, H. V. J., Tenni, B. F., Gleeson, D., & Lopert, R. (2016) · Global Public Health · doi:10.1080/17441692.2016.1256418 · Cited by 8
Self-citationPatents for second medical indications and their potential impact on pharmacare in Canada.
Scassa, T. (2001) · PubMed · Cited by 6
The Economics of the Trans-Pacific Partnership: Understanding the Alternative EstimatesPreprint
Ciuriak, D. (2016) · SSRN Electronic Journal · doi:10.2139/ssrn.2800588 · Cited by 3 · cited 1×
“A review of seven studies estimating the economic impact of the TPP (Ciuriak, 2016) concluded that those studies which were based more closely on the final TPP text make smaller estimates of impact.”
BackgroundCanada wins legal battle to set patent rules
Webster, P. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.1095168 · Cited by 1 · cited 1×
“Eli Lilly lost its claim against the Canadian Government in March 2017 (Webster, 2017).”
Background
Research works printed but not linked: 4
- Kelsey J (2013) Press release: Heavy-handed tactics in TPPA talks aim to isolate dissenters. Available at: https://itsourfuture.org.nz/heavy-handed-tactics-in-tppa-talks-aim-to-isolate-dissenters/ (accessed 28 May 2017).
- Pharmaceutical Research and Manufacturers of America (2013) PhRMA Urges Trans-Pacific Partnership negotiators to adopt a strong intellectual property framework. Available at: http://www.phrma.org/press-release/phrma-urges-trans-pacific-partnership-negotiators-to-adopt-a-strong-intellectual-property-framework (accessed 21 May 2017).
- Trans Pacific Partnership (2011) Intellectual property rights chapter draft, 10 February. Available at: http://keionline.org/sites/default/files/tpp-10feb2011-us-text-ipr-chapter.pdf (accessed 17 August 2013).
- Trans Pacific Partnership (2016) Trans Pacific Partnership Agreement chapter 18: Intellectual property. Available at: https://www.mfat.govt.nz/assets/_securedfiles/trans-pacific-partnership/text/18.-intellectual-property-chapter.pdf (accessed 9 June 2017).
Cited by
BitCoin: A new basket for eggs?
Qin, M., Su, C., & Tao, R. (2020) · Economic Modelling · doi:10.1016/j.econmod.2020.02.031 · Cited by 122
SHOULD BITCOIN BE HELD UNDER THE U.S. PARTISAN CONFLICT?
Su, C., Qin, M., Zhang, X.-L., Tao, R., & Umar, M. (2021) · Technological and Economic Development of Economy · doi:10.3846/tede.2021.14058 · Cited by 56
“Since then, there are new policies promulgated by the Trump administration, such as abolishing Obamacare, withdrawing from the Trans-Pacific Partnership (TPP) Agreement (Gleeson et al., 2018) and building walls at the U.S.–Mexico border, which can not be unified among Democrats and Republicans.”
BackgroundGleeson, D., Lexchin, J., Labonté, R., Townsend, B., Gagnon, M., Köhler, J. C., Forman, L., & Shadlen, K. C. (2019) · Globalization and Health · doi:10.1186/s12992-019-0518-2 · Cited by 51
“in Table 2 [23], though many of these were suspended in the CPTPP following the US withdrawal”
BackgroundSelf-citationThe politics of climate: Does factionalism impede U.S. carbon neutrality?
Qin, M., Su, Y. H., Zhao, Z., & Mirza, N. (2023) · Economic Analysis and Policy · doi:10.1016/j.eap.2023.04.039 · Cited by 40
Son, K., Lopert, R., Gleeson, D., & Lee, T.-J. (2018) · Globalization and Health · doi:10.1186/s12992-018-0423-0 · Cited by 35
Self-citation
Metadata
- Authors
- Gleeson, D., Lexchin, J., Lopert, R., & Kilic, B.
- Affiliations
- La Trobe University (AU)
- York University (CA)
- George Washington University (US)
- Public Citizen (US)
- Corresponding author
- Gleeson, Deborah
- Venue
- Global Social Policy
- Publisher
- SAGE Publications
- Published
- 2017-10-13
- Volume
- 18
- Issue
- 1
- Pages
- 7-27
- ISSN
- 1468-0181 (ISSN-L)
- 1741-2803
- PMC
- PMC5892849
- OpenAlex
- W2765265353
- Cited by
- 41
- References
- 37
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 4 · 2021: 5 · 2020: 10 · 2019: 6 · 2018: 4
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Global Social Policy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by-nc)
- La Trobe University
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Law › Intellectual Property Law
- Social Sciences › Business, Management and Accounting › Management of Technology and Innovation › Intellectual Property and Patents
- Keywords
- Trans-Pacific Partnership, intellectual property, pharmaceutical patents, access to medicines, generic drugs, developing countries, developed countries, trade agreements, drug exclusivity, US withdrawal from TPP
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.